Title of Study: A Phase 2 double-blind placebo-controlled study investigating the safety and efficacy of EDP1815 in the treatment of patients hospitalized with SARS-CoV-2 Infection
Loading…
Reload document 
Open in new tab Table of Contents
APL-9 IN ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19
To evaluate the safety of APL-9 (an investigational IV compound targeting the C3ba portion of the complement cascade) compared with that of placebo (as add-on therapy to standard of care [SOC], which can include Remdisivir, plasma, steroids) in subjects with coronavirus disease 2019 (COVID-19) who have mild to moderate respiratory failure. Any individual who is requiring oxygen and has x-ray changes would qualify to be screened. Contact person is Sabiha Hussain, PI. Of note, this trial does require the use of prophylactic broad-spectrum antibiotics while on study drug.
COVID-19 SPREAD AMONG FRONT-LINE HEALTHCARE WORKERS
A team of Rutgers physicians, led by co-principal investigators Dr. Martin Blaser, Dr. Jeffrey Carson and Dr. Reynold Panettieri, is conducting a critical COVID-19 study involving the spread of the virus among front-line healthcare workers. As part of the study, 250 asymptomatic RWJUH-New Brunswick physicians and employees involved in direct patient care will be tested for COVID-19, and undergo bloodwork and swabs over the course of several months. CLICK HERE to learn more. CLICK HERE if you are interested in participating in this study.
COVID-19 VACCINE
We need your help to test a COVID-19 vaccine.
Rutgers is committed to fighting the greatest public health challenge of this century. Will you join us?
As a member of the Rutgers community, you are invited to participate in upcoming clinical trials, including vaccine trials to prevent COVID-19. Trials are essential to understand how well vaccines work to protect our families and community.
Participation in these trials is free and completely voluntary. To be considered for the trial, visit the link https://redcap.link/Combat-COVID-19 to review the informed consent. You will then be asked questions about where you live and work, your medical history, and your contact information. If you are invited to take part in a trial, our research team will contact you with the information you will need to decide if you want to enroll. We may also contact you about other COVID-19 research.
We encourage you to share this information with others who may be interested joining.
Email Rutgers-COVID-Trials@rwjms.rutgers.edu if you have any questions.
Let’s act together as a community to fight COVID-19!